Global InformationPlexxikon information
| Company type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2001 |
| Founder | Joseph Schlessinger |
| Defunct | 2011 |
| Fate | Acquired by the Daiichi Sankyo |
| Headquarters | South San Francisco, California, United States. |
| Website | www |
Plexxikon is an American drug discovery company based in South San Francisco, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component, that it hopes will give a significant competitive advantage over other approaches.[citation needed][1]
In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.[2][3][4]
Daiichi Sankyo announced the shutdown of Plexxikon in 2022.[5]
- ^ "AI Drug Discovery: Key Trends and Developments in Pharmaceutical Industry". www.biopharmatrend.com. Retrieved 2023-09-11.
- ^ "Daiichi Sankyo to Acquire Plexxikon". Plexxikon. 2011-02-28. Archived from the original on 2011-03-06.
- ^ "Plexxikon acquired by Daiichi Sankyo". Haberman Associates. 2011-03-03. Retrieved 2020-08-06.
- ^ "Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition". BioSpace. Retrieved 2020-08-06.
- ^ Wells, Madeline (2022-01-12). "South SF company bought for $800 million is being shut down". SFGATE. Archived from the original on 2022-01-12.